Related Experiment Video
Updated: Aug 24, 2025
15:24
Testing Cancer Immunotherapeutics in a Humanized Mouse Model Bearing Human Tumors
Published on: December 16, 2022
3.2K
Challenges in the humanized mouse model for cancer: A commentary.
Eric Ramirez-Salazar1, Meenhard Herlyn1, Rajasekharan Somasundaram1
1The Wistar Institute, 3601 Spruce Street, Philadelphia, PA, USA.
Journal of Cancer Biology
|October 25, 2022
Summary
Mast cells in the tumor microenvironment drive therapy resistance by releasing cytokines. These cytokines reduce human leukocyte antigen (HLA) class I expression on cancer cells, hindering T cell-mediated killing.
Area of Science:
- Immunology
- Oncology
- Cancer Research
Background:
- The tumor microenvironment (TME) presents complex challenges in understanding cancer therapy resistance.
- Developing accurate animal models that replicate human diseases is crucial for advancing cancer treatment.
- Humanized mouse models offer new avenues for studying human immune cell interactions within tumors.
Purpose of the Study:
- To highlight the significant role of mast cells in immune therapy resistance within the TME.
- To explain the mechanisms by which mast cells contribute to treatment failure.
Main Methods:
- Utilizing a novel humanized mouse model to investigate human immune cells in tumor-host interactions.
- Analyzing the molecular crosstalk between mast cells and malignant cells in the TME.
Main Results:
- Mast cells were identified as key players in mediating immune therapy resistance.
- Mast cell-derived cytokines were shown to downregulate human leukocyte antigen (HLA) class I expression on tumor cells.
Conclusions:
- Mast cells contribute to immune evasion by making cancer cells less visible to cytotoxic T cells.
- Targeting mast cell activity may represent a novel strategy to overcome therapy resistance in cancer treatment.
